In recent years, the study of the brain glioma immune microenvironment has emerged as a compelling research area at the forefront of cancer research. Gliomas, a group of highly aggressive primary brain tumors, pose significant challenges to patients and clinicians due to their complex and heterogeneous nature. Understanding the intricate interplay between tumor cells and the immune system within the tumor microenvironment is paramount in developing effective therapeutic strategies. The immune microenvironment of brain gliomas constitutes a dynamic network of immune cells, stromal components, cytokines, and other factors that can either promote tumor growth or impede its progression. An evolving body of evidence suggests that this immune context significantly influences tumor development, invasion, and treatment response. Exploring the underlying mechanisms governing these interactions is crucial for unraveling the mysteries of glioma pathogenesis. Moreover, exploiting the immunotherapeutic potential to target gliomas has emerged as an attractive avenue for developing novel therapeutic approaches. Immunotherapies, such as immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and tumor vaccines, have demonstrated promising results in other cancer types. Translating these advancements to the realm of brain gliomas represents a tantalizing prospect for improving patient outcomes and survival rates.
The current state of research in the brain glioma immune microenvironment centers on investigating the underlying mechanisms that govern the crosstalk between tumor cells and immune components. By exploring the latest therapeutic strategies targeting the glioma immune landscape, we can potentially revolutionize glioma treatment and overcome immunotherapy resistance. This Research Topic aims to catalyze continued research, innovation, and collaboration among scientists, clinicians, and industry stakeholders. By unraveling and collecting insights into the mechanisms shaping the glioma immune landscape, understanding immunotherapy resistance, and advancing relevant translational research, we can pave the way toward more effective and personalized therapeutic interventions. This progress brings us one step closer to defeating the formidable challenge of brain gliomas and improving the lives of affected patients worldwide.
We welcome submissions of original research, cutting-edge reviews, clinical, pathological, and translational studies related to, but not limited to, the following areas:
(1) Mechanisms of crosstalk between glioma cells and the immune microenvironment, both in basic and clinical settings.
(2) Novel neoadjuvant treatment strategies for glioma immunotherapy, aiming to improve patient outcomes.
(3) Technical advancements in the detection of immunotherapy targets specific to glioma.
(4) New biomarkers that can guide and monitor the effectiveness of immunotherapy treatment in glioma patients.
(5) Pathological and molecular features of gliomas following immunotherapy to understand treatment responses and potential adverse effects.
(6) Prediction models for evaluating the pathologic response in glioma patients undergoing immunotherapy.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
In recent years, the study of the brain glioma immune microenvironment has emerged as a compelling research area at the forefront of cancer research. Gliomas, a group of highly aggressive primary brain tumors, pose significant challenges to patients and clinicians due to their complex and heterogeneous nature. Understanding the intricate interplay between tumor cells and the immune system within the tumor microenvironment is paramount in developing effective therapeutic strategies. The immune microenvironment of brain gliomas constitutes a dynamic network of immune cells, stromal components, cytokines, and other factors that can either promote tumor growth or impede its progression. An evolving body of evidence suggests that this immune context significantly influences tumor development, invasion, and treatment response. Exploring the underlying mechanisms governing these interactions is crucial for unraveling the mysteries of glioma pathogenesis. Moreover, exploiting the immunotherapeutic potential to target gliomas has emerged as an attractive avenue for developing novel therapeutic approaches. Immunotherapies, such as immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and tumor vaccines, have demonstrated promising results in other cancer types. Translating these advancements to the realm of brain gliomas represents a tantalizing prospect for improving patient outcomes and survival rates.
The current state of research in the brain glioma immune microenvironment centers on investigating the underlying mechanisms that govern the crosstalk between tumor cells and immune components. By exploring the latest therapeutic strategies targeting the glioma immune landscape, we can potentially revolutionize glioma treatment and overcome immunotherapy resistance. This Research Topic aims to catalyze continued research, innovation, and collaboration among scientists, clinicians, and industry stakeholders. By unraveling and collecting insights into the mechanisms shaping the glioma immune landscape, understanding immunotherapy resistance, and advancing relevant translational research, we can pave the way toward more effective and personalized therapeutic interventions. This progress brings us one step closer to defeating the formidable challenge of brain gliomas and improving the lives of affected patients worldwide.
We welcome submissions of original research, cutting-edge reviews, clinical, pathological, and translational studies related to, but not limited to, the following areas:
(1) Mechanisms of crosstalk between glioma cells and the immune microenvironment, both in basic and clinical settings.
(2) Novel neoadjuvant treatment strategies for glioma immunotherapy, aiming to improve patient outcomes.
(3) Technical advancements in the detection of immunotherapy targets specific to glioma.
(4) New biomarkers that can guide and monitor the effectiveness of immunotherapy treatment in glioma patients.
(5) Pathological and molecular features of gliomas following immunotherapy to understand treatment responses and potential adverse effects.
(6) Prediction models for evaluating the pathologic response in glioma patients undergoing immunotherapy.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
